- Why FIH Clinical Trial Budgets Are Hard to Estimate Early
- The Major Cost Drivers in a Medical Device FIH Study
- 1. Regulatory Strategy and Pre-Submission Work
- 2. Ethics and Regulatory Approval Timelines
- 3. Site Activation and Investigator Fees
- 4. Per-Patient Costs
- 5. Patient Enrollment and Screen Failure Rates
- 6. Data Management and Electronic Data Capture
- 7. Safety Monitoring and Adverse Event Reporting
- 8. Clinical Study Report and Submission Package
- How Program Structure Affects Total Clinical Trial Cost
- Geography as a Budget Variable
- Common Budget Mistakes to Avoid
- Building a Budget That Fits Your Capital Cycle
- Frequently Asked Questions
- Ready to Accelerate Your Clinical Program?
A clinical trial budget is one of the most consequential documents a medical device startup produces before first-in-human work begins. Underestimate it, and you burn through runway before hitting your enrollment target. Overestimate it without understanding where the money actually goes, and you either raise too much too early or price yourself out of a competitive CRO engagement.
This article breaks down the real cost drivers in a first-in-human (FIH) medical device study — the line items that inflate budgets, the structural decisions that compress them, and how geography changes the math in ways most founders don't model until it's too late.
Why FIH Clinical Trial Budgets Are Hard to Estimate Early
Most founders anchor their clinical trial budget on a single number — usually the CRO management fee — and treat everything else as a minor variable. That framing is wrong. The CRO fee is one component of a budget that spans regulatory strategy, ethics approvals, site activation, patient enrollment, data management, safety monitoring, and submission preparation. Each of those workstreams carries its own cost curve, and several interact in ways that multiply the total.
The second common mistake is treating a U.S.-based CRO quote as the only benchmark. U.S. and EU trial infrastructure is built for large pharma programs: multi-site Phase III studies with enterprise data systems, centralized IRBs, and site networks sized for hundreds of patients. When a startup with $2 million allocated for FIH work receives a quote designed for that infrastructure, the numbers rarely fit — and neither does the timeline.
Understanding where cost actually accumulates is the first step toward building a budget that survives contact with reality.
The Major Cost Drivers in a Medical Device FIH Study
1. Regulatory Strategy and Pre-Submission Work
Before a single patient is enrolled, you need a clear FDA pathway and a protocol that will generate data FDA will accept. That means Pre-Sub meetings, IDE preparation where applicable, and protocol architecture aligned to your intended 510(k), De Novo, PMA, or HDE route.
This workstream is consistently underbudgeted because it feels like planning rather than execution. But a protocol that misaligns with your intended regulatory pathway can force a mid-study amendment — and amendments cost both time and money. A protocol rework after site activation can set a program back by months, which in startup terms means another quarter of overhead without data.
Solid regulatory strategy at the front end is one of the most cost-efficient investments in the entire budget. The FIH-12™ program at bioaccess® anchors regulatory strategy to the sponsor's intended U.S. FDA pathway from day one, across all nine workstreams, so the evidence package is submission-ready without rework at the end.
2. Ethics and Regulatory Approval Timelines
Approval timelines directly affect burn rate. Every month a study sits in a regulatory queue is a month of overhead: staff salaries, device inventory carrying costs, site readiness maintenance, and deferred data.
In the U.S. and EU, ethics and regulatory approvals typically take 6 to 12 months. In Panama, El Salvador, Chile, and the Dominican Republic, the same approvals are observed in 30 to 90 days. That difference alone can represent several hundred thousand dollars in carrying costs for a startup maintaining a standing team while waiting.
This is not a logistics preference. It is a material budget variable. A startup with $3 million in FIH budget and a 9-month regulatory queue in the U.S. may arrive at first enrollment with $500,000 already consumed in overhead before a single patient is screened.
3. Site Activation and Investigator Fees
Site activation covers site qualification, contract negotiation, Ethics Committee (EC) submissions at the site level, and investigator training. For a multi-site study, these costs multiply. A single site activation at a U.S. academic medical center can run $50,000 to $100,000 before any patient is seen — accounting for feasibility assessments, contract cycles, and EC submission fees.
Investigator fees vary significantly by country and specialty. Device trials requiring surgical implantation or specialized procedural skills command higher per-procedure fees than simpler interventional studies. Budgeting accurately here requires knowing your device category, the investigator profile your protocol demands, and the site's patient volume in your target indication.
Working with a network of pre-qualified sites reduces activation time and lowers the cost of feasibility work. bioaccess® operates across 50-plus pre-qualified sites across 19 Latin American and Caribbean markets, which means that infrastructure does not need to be rebuilt from scratch for each new sponsor. That translates directly into lower activation cost and faster time to first patient.
4. Per-Patient Costs
Per-patient cost is the line item that most clearly separates U.S. and EU trial execution from Latin American execution. In the U.S., per-patient costs for a FIH device study routinely reach six figures when you include site fees, investigator fees, protocol-required diagnostics, and patient management. That cost structure is incompatible with a $1 million to $3 million FIH budget unless your sample size is very small.
In Panama, per-patient costs range from $12,000 to $22,000. That figure covers the clinical work at the site level and reflects the cost structure of a pre-qualified site operating under ISO 14155 and FDA 21 CFR Part 812.28. It is specific to Panama; costs vary across other markets in the 19-country network.
The practical effect: a 20-patient FIH study that would consume $2 million to $3 million in per-patient costs in the U.S. can be executed in Panama for $240,000 to $440,000 in per-patient costs. That difference funds the rest of the program — regulatory strategy, data management, safety monitoring, and submission preparation — with capital to spare.
5. Patient Enrollment and Screen Failure Rates
Enrollment is where most FIH budgets experience their largest unplanned overruns. The primary causes are overly optimistic enrollment rate assumptions and underestimated screen failure rates.
Eligibility criteria in medical device FIH studies tend to be narrow. You may need a specific anatomical profile, a defined disease severity range, or a prior treatment history. Screen failure rates of 30 to 50 percent are common in device studies. If your budget assumes a one-to-one screening-to-enrollment ratio, you will run out of money before hitting your sample size.
Enrollment costs include patient stipends, screening visits, protocol-required diagnostics, and site staff time per patient contact. In markets with strong patient availability for your indication and experienced site coordinators, these costs are lower and enrollment moves faster. Site selection decisions made at the protocol design stage — not after site activation — are the most effective lever for managing enrollment cost.
6. Data Management and Electronic Data Capture
Electronic data capture (EDC) setup, data entry, query resolution, and database lock are both fixed and variable costs that scale with protocol complexity and visit count. A lean protocol with fewer endpoints and fewer visits costs less to manage than a heavily instrumented study.
This is worth considering at the protocol design stage. Every additional data collection point adds EDC configuration time, site training time, and query volume. A protocol with 40 data fields per visit costs meaningfully more to manage than one with 20, and that difference compounds across every patient and every visit.
Data collected under ISO 14155 and structured per FDA 21 CFR Part 812.28 is accepted for U.S. IDE and IND submissions. That standard matters for budget planning because it determines whether the data collected in Latin America can go directly into your FDA submission package or requires rework. Re-formatting, re-validating, or re-collecting data that was not captured to the right standard is an unplanned cost that can derail a submission timeline.
7. Safety Monitoring and Adverse Event Reporting
Safety monitoring is a fixed operational cost that scales with patient count and protocol risk classification. A Data Safety Monitoring Board (DSMB), if required, adds both direct fees and coordination overhead. Adverse event (AE) reporting obligations under GCP and ISO 14155 require trained clinical operations staff at the site level and sponsor level.
Underestimating safety monitoring costs is common in early-stage budgets because founders focus on clinical execution and treat safety infrastructure as a compliance checkbox. In practice, a serious adverse event (SAE) that is not managed correctly — reported late, documented incompletely, or escalated through the wrong channel — can trigger a clinical hold or a regulatory inquiry that costs far more than the monitoring infrastructure would have.
bioaccess® maintains ACRP-certified clinical operations under NCCA accreditation, reflecting the standard of training required to manage this workstream correctly across multiple sites and countries.
8. Clinical Study Report and Submission Package
The clinical study report (CSR) and supporting submission package are the deliverables that justify the entire budget. A CSR that does not meet FDA's expectations for format, completeness, or statistical presentation will require revision — and revision cycles at the submission stage are expensive, both in fees and in the time they add to your regulatory timeline.
Budgeting for a submission-ready evidence package from the start, rather than treating the CSR as a post-study add-on, changes how you scope the data management and medical writing workstreams. The FIH-12™ program structures the submission package as a defined deliverable within the 12-month engagement, not a separate project that begins after database lock.
How Program Structure Affects Total Clinical Trial Cost
The structure of your CRO engagement affects total cost as much as geography does. A fragmented model — where regulatory strategy, site operations, data management, and medical writing are handled by separate vendors — introduces coordination overhead, version control risk, and accountability gaps that inflate both cost and timeline.
Single-team accountability across all workstreams removes that overhead. When the team managing your FDA Pre-Sub is the same team managing site activation and data collection, protocol amendments are handled internally rather than through a multi-vendor change order process. That structural efficiency has a direct effect on how much of your budget reaches patient care versus administrative coordination.
The Cook Group multi-site FIH study, which involved 142-plus INVIMA regulatory submissions managed across Colombia, illustrates what operational scale looks like when site relationships and regulatory infrastructure are already in place. That infrastructure does not need to be built from scratch for each new sponsor.
Geography as a Budget Variable
Geography is the single largest controllable variable in a FIH clinical trial budget. The three dimensions that matter are regulatory approval timelines, per-patient costs, and site quality relative to FDA data standards.
U.S. and EU sites offer regulatory familiarity but carry cost structures and approval timelines that are incompatible with startup capital cycles. Latin American markets — specifically Panama, El Salvador, Chile, and the Dominican Republic for the 30-to-90-day approval window — offer a combination of speed, cost, and data quality that changes the budget math fundamentally.
The critical qualifier is data bridgeability. Running a study in Latin America only saves money if FDA accepts the data for your U.S. submission. Data collected under ISO 14155 and structured per FDA 21 CFR Part 812.28 meets that standard. The Establishment Labs case study — where LATAM clinical evidence supported FDA PMA approval for Motiva® implants — is a documented example of that pathway working at the PMA level.
ClarVista Medical's trajectory, from first-in-human to Alcon acquisition, followed the same logic: FIH execution in Latin America, FDA-bridgeable data, and a clinical evidence package that supported the downstream commercial outcome.
Common Budget Mistakes to Avoid
Anchoring on the CRO fee alone. The management fee is one line item. Regulatory approvals, site activation, enrollment, data management, safety monitoring, and submission preparation are separate cost centers that together typically exceed the management fee.
Assuming U.S. approval timelines in a Latin American study. If your budget models a 90-day approval window but your CRO's site network is not in the countries where that window is observed, you will not hit that timeline. Approval speed is country-specific, not region-wide.
Using a one-to-one screening-to-enrollment ratio. Screen failure rates in device FIH studies are routinely 30 to 50 percent. Budget for the screening visits, not just the enrolled patients.
Treating the CSR as a post-study project. Medical writing and submission preparation take time and cost money. If they are not scoped into the original budget, they become an unplanned cost that delays your filing.
Ignoring carrying costs during the approval queue. Every month between protocol finalization and first patient enrolled costs money. Staff, device inventory, site readiness, and sponsor overhead do not pause while approvals are pending.
Fragmenting vendors across workstreams. Coordination overhead between a regulatory consultant, a site management organization, a data management vendor, and a medical writer adds cost and risk that a single-team engagement avoids.
Building a Budget That Fits Your Capital Cycle
A FIH budget that fits your capital cycle is not the cheapest budget — it is the one that delivers a submission-ready evidence package within the runway your next funding round requires.
That means modeling the full cost stack: regulatory strategy, approval timeline carrying costs, site activation, per-patient costs at realistic screen failure rates, data management, safety monitoring, and submission preparation. It means choosing geography based on both cost and data standards, not cost alone. And it means structuring your CRO engagement so that accountability for all nine workstreams sits with one team.
If your FIH budget is being built or stress-tested, the FIH Launch Planner at bioaccessla.com generates a preliminary country route, timeline range, and evidence package estimate by device class based on six questions. It is a starting point, not a quote — but it gives you a grounded framework before you issue an RFP.
Intake for the FIH-12™ program is capped at 8 new programs per quarter. If your IDE approval or Series A close is approaching, that capacity constraint is worth factoring into your planning timeline.
Frequently Asked Questions
What is a clinical trial budget for a medical device FIH study?
A clinical trial budget for a first-in-human medical device study is a comprehensive cost plan covering regulatory strategy and Pre-Sub work, ethics and regulatory approval timelines, site activation, per-patient costs, data management, safety monitoring, and clinical study report preparation. It should account for all workstreams from protocol development through FDA submission — not just the CRO management fee.
What are the biggest cost drivers in a first-in-human clinical trial budget?
The largest cost drivers are per-patient costs, regulatory approval timeline carrying costs, site activation fees, and screen failure rates during enrollment. Approval timelines are particularly significant for startups because every month in a regulatory queue consumes overhead without generating data.
How much does a first-in-human trial cost per patient in Latin America versus the U.S.?
Per-patient costs in Panama range from $12,000 to $22,000 under the bioaccess® FIH-12™ program. U.S. per-patient costs for a device FIH study routinely reach six figures when site fees, investigator fees, and protocol-required diagnostics are included. For a startup with a $1 million to $5 million FIH budget, that difference is material.
Is data collected in Latin America accepted by FDA for IDE and IND submissions?
Yes, when collected under ISO 14155 and structured per FDA 21 CFR Part 812.28. That standard governs foreign clinical data acceptance for U.S. submissions. bioaccess® collects and structures data to that standard, making the evidence package submission-ready without rework.
How do ethics and regulatory approval timelines affect a FIH clinical trial budget?
Directly. Every month between protocol finalization and first patient enrolled is a month of overhead — staff, device inventory, site readiness, and sponsor operations. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30 to 90 days. In the U.S. and EU, the same approvals typically take 6 to 12 months. For a startup, that gap can represent several hundred thousand dollars in carrying costs.
What is the most common budget mistake in medical device FIH studies?
Anchoring the entire budget on the CRO management fee while treating regulatory approvals, site activation, enrollment, data management, and submission preparation as secondary variables. In practice, those workstreams together often exceed the management fee — and underestimating any one of them creates unplanned overruns that compress the runway available for the next funding milestone.
How many programs does bioaccess® accept per quarter?
Intake is capped at 8 new programs per quarter across the FIH-12™ program. This is a capacity constraint, not a marketing claim. Sponsors whose IDE approval or Series A close is approaching should factor that constraint into their planning timeline.
Ready to Accelerate Your Clinical Program?
Book a meeting with our team to discuss how bioaccess® can fast-track your clinical trials or market entry in Latin America.
Leave a Reply